QUEBEC, Canada — February 17, 2026 — Leads & Copy —
Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF) has announced the formal filing of a proprietary Thykamine™ fingerprint in two recent patent applications. This fingerprint will be a core component of the company’s long-term intellectual property and patent strategy and will be systematically incorporated into all future Thykamine™-related patent filings.
The Thykamine™ fingerprint defines eight specific chemical components present in precise ratios, established using advanced High-Performance Liquid Chromatography–Mass Spectrometry (HPLC-MS) analytical methods. According to Devonian, the HPLC-MS methodology has demonstrated high reproducibility across manufactured batches of Thykamine™. This result has been independently confirmed by Nuclear Magnetic Resonance (NMR) analysis, showing ≥98% confidence in batch-to-batch consistency.
Batch reproducibility was further validated through potency assays using a U-937 human cell-based model. According to the company, every batch of Thykamine™ exhibits equivalent biological activity. These assays confirmed consistent inhibition of key inflammatory cytokines, including RANTES and MIP-1β, reinforcing the functional equivalence of each production batch. The potency assay is currently being validated for inclusion in the Chemistry, Manufacturing and Controls (CMC) section of Thykamine™ production.
According to Devonian, the HPLC-MS fingerprinting, NMR confirmation, and potency assays will form an integral part of its CMC framework for Thykamine™ production. The company believes this reinforces regulatory preparedness and ensures the level of manufacturing robustness required for pharmaceutical development.
Dr. André Boulet, Chief Executive Officer of Devonian, stated that these analytical and biological methods clearly demonstrate the quality and consistency of Thykamine™ produced in every batch, both chemically and as an active anti-inflammatory and anti-fibrotic pharmaceutical. He added that this integrated approach provides strong confidence that patients will consistently receive a product of the same high quality, efficacy, and reliability.
Devonian’s Thykamine™, the first pharmaceutical product issued from the company’s SUPREX™ platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. According to the company, the anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.
Devonian Health Group Inc. specializes in the development of drugs for various auto-immune fibroinflammatory diseases with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.
Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).
Source: Devonian Health Group Inc.
